Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity

作者：Alessio Cortellini, Edoardo Garbo, Giulia La Cava, Fabrizio Citarella, Valentina Santo, Leonardo Brunetti, David J. Pinato, Jarushka Naidoo, Monica Loza, Carlo Genova, Scott Gettinger, So Yeon Kim, Ritujith Jayakrishnan, Talal El Zarif, Marco Russano, Federica Pecci, Alessandro Di Federico, Michele Montrone, Dwight H. Owen, Diego Signorelli, Mingjia Li, Andrea Camerini, Balázs Halmos, Bruno Vincenzi, Giulio Metro, Sai Yendamuri, Francesco Grossi, Eleni Josephides, Bartłomiej Tomasik, Raffaele Giusti, Emilio Bria, Martin Sebastian, Maximilian Rost, Fabian Acker, Lorenza Landi, Francesca Mazzoni, Alessandro Morabito, Alessandro Leonetti, Luca Cantini, Giannis Mountzios, Sukumar Kalvapudi, David O’Reilly, Eleni Karapanagiotou, Isabelle Monnet, Javier Baena, Marianna Macerelli, Margarita Majem, A. Piedra, Diego Cortinovis, Giuseppe Tonini, Gabriele Minuti, Laura Mezquita, Teresa Gorría, Teresa Beninato, Giuseppe Lo Russo, Arsela Prelaj, Andrea De Giglio, Federica Biello, Frank Aboubakar Nana, Anne‐Marie C. Dingemans, Joachim G.J.V. Aerts, Roberto Ferrara, Taher Abu Hejleh, Kazuki Takada, Abdul Rafeh Naqash, Marina Chiara Garassino, Heather A. Wakelee, Amin H. Nassar, Biagio Ricciuti, Paolo Soda, Camillo Maria Caruso, Valerio Guarrasi · 发表于：Lung Cancer · 年份：2025 · DOI：10.1016/j.lungcan.2025.108799 · 被引用次数：1 · 研究领域：Cancer Immunotherapy and Biomarkers、Radiomics and Machine Learning in Medical Imaging、Ferroptosis and cancer prognosis